Overview

Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)

Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to determine the effect of Lanreotide on polycystic liver and kidneys in patients with autosomal dominant polycystic kidney disease.
Details
Lead Sponsor:
Radboud University
Collaborator:
Ipsen
Treatments:
Angiopeptin
Lanreotide
Somatostatin